Could CAR-T cells tame multiple sclerosis? early trial launches

NCT ID NCT07303790

Recruiting now Disease control Sponsor: Daishi Tian Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early study tests a single dose of GC012F CAR-T cell injection in 9 people with multiple sclerosis. The main goal is to check safety and tolerability, not yet to see if it works. Researchers will monitor side effects for up to 15 years and measure how the cells behave in blood and spinal fluid.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GC012F CAR-T cell injection
What this could lead to: If successful, this could point toward a new way to control multiple sclerosis by targeting immune cells that attack the nervous system.
What could go wrong: This is a very early, tiny trial (9 people) focused only on safety. It is too soon to know if it works, and CAR-T therapy carries risks like severe immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology
RECRUITING

Hubei, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.